Pancreatic duct drainage treatment for hypertriglyceridemic pancreatitis: efficacy and recurrence rate analysis
10.3760/cma.j.cn113884-20240516-00145
- VernacularTitle:胰管支架置入治疗高脂血症性胰腺炎的短期和长期疗效研究
- Author:
Jie WEI
1
;
Chengsi ZHAO
;
Weijie YAO
;
Qing XU
;
Zuozheng WANG
Author Information
1. 宁夏医科大学总医院，银川 750004
- Keywords:
Pancreatitis;
Hypertriglyceridemia;
Pancreatic duct stent;
Efficacy
- From:
Chinese Journal of Hepatobiliary Surgery
2024;30(9):666-671
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To systematically analyze the short-term and long-term efficacy of pancreatic stent placement in the treatment of hyperlipidemic pancreatitis (HTGP).Methods:This retrospective case-control study included 66 HTGP patients who received treatment at the General Hospital of Ningxia Medical University from January 1, 2017 to June 1, 2020. Among them, 53 were male and 13 were female, with an age of (39.67±9.99) years. Patients were divided into stent group (20 cases) and conservative group (46 cases) based on whether they received pancreatic stent placement treatment. The main observation indicators included symptom relief, biochemical index recovery, recurrence rate, and incidence of complications.Results:In terms of short-term efficacy, compared with the conservative group, the stent group showed significantly better acute physiology and chronic health evaluation II scores [(2.85±1.66) vs. (4.59±2.60), P=0.008], lower incidence of organ failure [15.0% (3/20) vs. 41.3% (19/46), P=0.037], and lower incidence of short-term complications [10.0% (2/20) vs. 60.9% (28/46), P=0.012], all of which were statistically significant. In terms of long-term efficacy, the median time to first recurrence was significantly longer in the stent group (15 months) compared to the conservative group (12 months) ( Z=2.04, P=0.042). However, there was no statistically significant difference in recurrence rates between the two groups [50.0% (9/18) vs. 57.9% (22/38), P=0.579]. The incidence of late complications was also significantly lower in the stent group [5.6% (1/18) vs. 31.6% (12/38), P=0.042]. Conclusions:Pancreatic stent placement therapy has significant advantages in improving short-term symptoms and reducing the incidence of complications in HTGP patients, but the overall recurrence rate do not significantly decrease.
